Please provide your email address to receive an email when new articles are posted on . “Negative symptoms” like social withdrawal as well as a history of stimulant use were predictors of a patient’s ...
Bristol Myers Squibb BMY recently announced that it will continue the phase III ADEPT-2 study on Cobenfy in psychosis associated with Alzheimer's disease. The decision to continue the study follows a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results